Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 269

1.

First- versus second-generation drug-eluting stents for the treatment of coronary bifurcations.

Costopoulos C, Latib A, Ferrarello S, Naganuma T, Sticchi A, Filippo F, Giannini F, Basavarajaiah S, Kawaguchi M, Naim C, Candreva A, Carlino M, Chieffo A, Montorfano M, Colombo A.

Cardiovasc Revasc Med. 2013 Nov-Dec;14(6):311-5. doi: 10.1016/j.carrev.2013.09.006. Epub 2013 Oct 21.

PMID:
24157311
2.

Long-term clinical outcomes after percutaneous coronary intervention for ostial/mid-shaft lesions versus distal bifurcation lesions in unprotected left main coronary artery: the DELTA Registry (drug-eluting stent for left main coronary artery disease): a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment.

Naganuma T, Chieffo A, Meliga E, Capodanno D, Park SJ, Onuma Y, Valgimigli M, Jegere S, Makkar RR, Palacios IF, Costopoulos C, Kim YH, Buszman PP, Chakravarty T, Sheiban I, Mehran R, Naber C, Margey R, Agnihotri A, Marra S, Capranzano P, Leon MB, Moses JW, Fajadet J, Lefevre T, Morice MC, Erglis A, Tamburino C, Alfieri O, Serruys PW, Colombo A.

JACC Cardiovasc Interv. 2013 Dec;6(12):1242-9. doi: 10.1016/j.jcin.2013.08.005.

3.

Everolimus-eluting stents versus sirolimus- or paclitaxel-eluting stents: two-year results from the Guthrie Health Off-Label Stent (GHOST) registry.

Harjai KJ, Kondareddy S, Pinkosky B, Harjai N, Orshaw P, Boura J.

J Interv Cardiol. 2013 Apr;26(2):153-62. doi: 10.1111/j.1540-8183.2013.12016.x. Epub 2013 Jan 31.

PMID:
23363439
4.

Two-year follow-up of outcomes of second-generation everolimus-eluting stents versus first-generation drug-eluting stents for stenosis of saphenous vein grafts used as aortocoronary conduits.

Kitabata H, Loh JP, Pendyala LK, Badr S, Dvir D, Barbash IM, Minha S, Torguson R, Chen F, Satler LF, Suddath WO, Kent KM, Pichard AD, Waksman R.

Am J Cardiol. 2013 Jul 1;112(1):61-7. doi: 10.1016/j.amjcard.2013.02.055. Epub 2013 Apr 2.

PMID:
23561590
5.

Second-generation versus first-generation drug-eluting stents for the treatment of patients with acute coronary syndromes and obstructive coronary artery disease.

Machado C, Raposo L, Dores H, Leal S, Campante Teles R, de Araújo Gonçalves P, Mesquita Gabriel H, Almeida M, Mendes M.

Coron Artery Dis. 2014 May;25(3):208-14. doi: 10.1097/MCA.0000000000000078.

PMID:
24419038
6.

Treatment of coronary bifurcation lesions with drug-eluting stents: insights from the first phase of the prospective multicenter german drug-eluting stent registry.

Abdel-Wahab M, Nienaber CA, Mostafa AE, Ferenc M, Silber S, Sabin G, Tebbe U, Akin I, Hochadel M, Senges J, Kuck KH, Richardt G; German Drug-Eluting Stent (DES.DE) Registry.

J Interv Cardiol. 2012 Aug;25(4):344-52. doi: 10.1111/j.1540-8183.2011.00718.x. Epub 2012 Mar 12.

PMID:
22409587
7.

4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention).

Taniwaki M, Stefanini GG, Silber S, Richardt G, Vranckx P, Serruys PW, Buszman PE, Kelbaek H, Windecker S; RESOLUTE All-Comers Investigators.

J Am Coll Cardiol. 2014 Apr 29;63(16):1617-25. doi: 10.1016/j.jacc.2013.12.036. Epub 2014 Feb 13.

8.

Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.

Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, Bhatt DL, Slater J.

Circulation. 2012 Jun 12;125(23):2873-91. doi: 10.1161/CIRCULATIONAHA.112.097014. Epub 2012 May 14.

9.

The role of everolimus-eluting and resolute zotarolimus-eluting stents in the treatment of coronary bifurcations.

Ferrarello S, Costopoulos C, Latib A, Naganuma T, Sticchi A, Figini F, Basavarajaiah S, Carlino M, Chieffo A, Montorfano M, Kawaguchi M, Naim C, Giannini F, Colombo A.

J Invasive Cardiol. 2013 Sep;25(9):436-40.

10.

Safety and efficacy outcomes of overlapping second-generation everolimus-eluting stents versus first-generation drug-eluting stents.

Kitabata H, Loh JP, Pendyala LK, Badr S, Dvir D, Barbash IM, Minha S, Torguson R, Chen F, Satler LF, Suddath WO, Kent KM, Pichard AD, Waksman R.

Am J Cardiol. 2013 Oct 15;112(8):1093-8. doi: 10.1016/j.amjcard.2013.05.054. Epub 2013 Jul 2.

PMID:
23827397
11.

Long-term comparative analysis from an all-comer cohort of coronary patients treated using first- and second-generation drug-eluting stents.

Codner P, Bental T, Assali A, Vaknin-Assa H, Lev E, Kornowski R.

J Invasive Cardiol. 2014 Aug;26(8):378-84.

12.

Sirolimus- versus paclitaxel-eluting stents for the treatment of coronary bifurcations results: from the COBIS (Coronary Bifurcation Stenting) Registry.

Song YB, Hahn JY, Choi SH, Choi JH, Lee SH, Jeong MH, Kim HS, Seong IW, Yang JY, Rha SW, Jang Y, Yoon JH, Tahk SJ, Seung KB, Park SJ, Gwon HC.

J Am Coll Cardiol. 2010 Apr 20;55(16):1743-50. doi: 10.1016/j.jacc.2010.02.008.

13.

A propensity score matched analysis to determine if second-generation drug-eluting stents outperform first-generation drug-eluting stents in a complex patient population.

Loh JP, Pendyala LK, Kitabata H, Badr S, Torguson R, Chen F, Satler LF, Suddath WO, Pichard AD, Waksman R.

Int J Cardiol. 2013 Dec 5;170(1):43-8. doi: 10.1016/j.ijcard.2013.10.004. Epub 2013 Oct 12.

PMID:
24169532
14.

Clinical outcomes after zotarolimus and everolimus drug eluting stent implantation in coronary artery bifurcation lesions: insights from the RESOLUTE All Comers Trial.

Diletti R, Garcia-Garcia HM, Bourantas CV, van Geuns RJ, Van Mieghem NM, Vranckx P, Zhang YJ, Farooq V, Iqbal J, Wykrzykowska JJ, de Vries T, Swart M, Teunissen Y, Negoita M, van Leeuwen F, Silber S, Windecker S, Serruys PW; RESOLUTE All Comers Investigators.

Heart. 2013 Sep;99(17):1267-74. doi: 10.1136/heartjnl-2013-303778. Epub 2013 Jun 25.

PMID:
23800571
15.

Differential Prognostic Effect Between First- and Second-Generation Drug-Eluting Stents in Coronary Bifurcation Lesions: Patient-Level Analysis of the Korean Bifurcation Pooled Cohorts.

Lee JM, Hahn JY, Kang J, Park KW, Chun WJ, Rha SW, Yu CW, Jeong JO, Jeong MH, Yoon JH, Jang Y, Tahk SJ, Gwon HC, Koo BK, Kim HS.

JACC Cardiovasc Interv. 2015 Aug 24;8(10):1318-31. doi: 10.1016/j.jcin.2015.05.014.

17.

Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis.

Bangalore S, Toklu B, Amoroso N, Fusaro M, Kumar S, Hannan EL, Faxon DP, Feit F.

BMJ. 2013 Nov 8;347:f6625. doi: 10.1136/bmj.f6625.

18.
19.

Comparison of 5-year clinical outcomes between sirolimus-versus paclitaxel-eluting stent: Korean multicenter network analysis of 9000-patient cohort.

Park K, Park KW, Rha SW, Bae JH, Hur SH, Park JS, Yoon JH, Jang Y, Jeong MH, Kim HS.

Circ Cardiovasc Interv. 2012 Apr;5(2):174-84. doi: 10.1161/CIRCINTERVENTIONS.111.964650. Epub 2012 Mar 6.

20.

Supplemental Content

Support Center